Back to results
US 2013/0210827 A1Published application
Novel benzenesulfonamides as calcium channel blockers
AssigneeAbbVie Inc.
InventorsQingwei Zhang, Andrew O. Stewart, Zhiren Xia
Life of this patent
Estimating the term…
Abstract
The present application relates to calcium channel inhibitors comprising compounds of formula (I), formula (II), formula (III), or formula (IV), wherein L1, R1, R2, R3, R4, R5, R6, R7 and Rc are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
Claims23
A compound of formula (I) or (II),
- or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein
- one of R1 and R2 is X, and the other of R1 and R2 is Y;
- X is (i) or (ii);
- m and n, at each occurrence, are independently 1 or 2;
- G1 is azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or azepanyl, wherein G1 is connected through the nitrogen atom of said azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or azepanyl;
- Y is —NRcAr1, —NRcAr2—Ar1, —NRcCH(Ar1)2, —NRc(CRaRb)pAr1, —NRc(CRaRb)pCH(Ar1)2, —NRc-G2, —NRc-G2-Ar1, (iii), (iv), (v) or (vi);
- Ar1, at each occurrence, is independently aryl or heteroaryl, wherein said aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3, or 4, or 5 substituents selected from alkoxy, alkyl, cyano, haloalkyl, halogen, or —N(alkyl)2;
- Ar2 is aryl or heteroaryl, wherein said aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from alkoxy, alkyl, cyano, haloalkyl, or halogen;
- G2 is cycloalkyl;
- Ra and Rb are at each occurrence independently hydrogen, alkyl, or hydroxyalkyl;
- Rc is hydrogen or alkyl;
- p is 1, 2, 3, or 4;
- and
- R3, R4, R5 and R6 are each independently hydrogen, alkoxy, alkyl, or halogen.
11 more elements
A compound of formula (ITT) or (IV),
- or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, wherein
- L1 is C(O) or S(O)2;
- R2 is X;
- X is (i) or (ii);
- m and n, at each occurrence, are independently 1 or 2;
- G1 is azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or azepanyl, wherein G1 is connected through the nitrogen atom of said azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or azepanyl;
- R3, R4, R5 and R6 are each independently hydrogen, alkoxy, alkyl, or halogen;
- R7 is S(O)2Ar3, —C(O)Ar3, S(O)2(CRaRb)pAr3, —C(O)(CRaRb)pAr3, —S(O)2(CRaRb)pCH(Ar3)2, —C(O)(CRaRb)pCH(Ar3)2, —C(O)CH(Ar3)2, or —CH(Ar3)2;
- Ar3, at each occurrence, is aryl or heteroaryl, wherein said aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from alkoxy, alkyl, cyano, haloalkyl, or halogen;
- Ra and Rb are at each occurrence independently hydrogen, alkyl, or hydroxyalkyl;
- p is 1, 2, 3, or 4;
- and
- RcC is hydrogen or alkyl.
10 more elements
A method of treating pain in a subject in need thereof, comprising:
- administering to the subject a therapeutically suitable amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof, wherein the pain is acute pain, chronic pain, neuropathic pain, inflammatory pain, visceral pain, cancer pain, allodynia, fibromyalgia, sciatica, back pain, and headache pain including migraine, or combinations thereof.
A method of treating disorders of the central nervous system in a subject in need thereof, comprising the step of:
- administering a therapeutically suitable amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof, wherein the disorders of the central nervous system include stroke, epilepsy, manic depression, bipolar disorders, depression, anxiety, schizophrenia, migraine, and psychoses;
- neural degenerative disorders including Alzheimer's disease, AIDS related dementia, Parkinson's disease, neuropathy caused by head injury, and dementia caused by cerebrovascular disorders;
- disorders of the lower urinary tract including overactive bladder, prostatis, prostadynia, interstitial cystitis, and benign prostatic hyperplasia;
- disorders caused by psychogenic stress including bronchial asthma, unstable angina, and hypersensitive colon inflammation;
- cardiovascular disorders including hypertension, atherosclerosis, heart failure, and cardiac arrhythmias;
- drug addiction withdrawal symptoms, including ethanol addiction withdrawal symptoms;
- skin disorders including pruritis and allergic dermatitis, inflammatory bowel disease;
- cancer;
- diabetes;
- and infertility and sexual dysfunction, or combinations thereof.
7 more elements
Dependencies are inferred from the claim text.